We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 74

U.S. Supreme Court refines & limits antitrust state action defense
  • Kilpatrick Townsend & Stockton LLP
  • USA
  • February 26 2015

On February 25, 2015, the United States Supreme Court issued a 6-3 opinion in North Carolina State Bd of Dental Examiners v. FTC, which held that a


Reversal based on obviousness potentially impacts patent rights of stem cell technology
  • Kilpatrick Townsend & Stockton LLP
  • USA
  • May 11 2010

In a decision potentially affecting the ability of biotechnology companies and research institutions to obtain and maintain patent rights concerning stem cell technology, the United States Patent and Trademark Office’s Board of Patent Appeals and Interferences (“BPAI”) recently rejected the claims of U.S. Patent Number 7,029,913 (the “‘913 Patent”) directed to human embryonic stem cell lines


FTC v. St. Luke's Health System, Ltd.: Ninth Circuit holds that acquisition of physician group practice violates antitrust laws, requires divestiture
  • Kilpatrick Townsend & Stockton LLP
  • USA
  • February 11 2015

On February 10, 2015, the Ninth Circuit affirmed a district court ruling in favor of the Federal Trade Commission that the acquisition of an Idaho


FTC v. Actavis
  • Kilpatrick Townsend & Stockton LLP
  • USA
  • June 21 2013

On June 17, 2013, the Supreme Court issued an opinion authored by Justice Breyer in FTC v. Actavis, holding that "reverse payment" settlements are


FTC v. Phoebe Putney Health System, Inc., et al.
  • Kilpatrick Townsend & Stockton LLP
  • USA
  • February 20 2013

On February 19, 2013, the United States Supreme Court in Federal Trade Commission v. Phoebe Putney Health System, Inc., et al., unanimously rejected


11th Circuit upholds Broward County
  • Kilpatrick Townsend & Stockton LLP
  • USA
  • August 21 2012

Yesterday, the US Court of Appeals for the 11th Circuit upheld summary judgment in favor of the employer in Seff v. Broward County


Medical syringe company finds competitors’ mark a sticking point; pricks its ire
  • Kilpatrick Townsend & Stockton LLP
  • USA
  • August 21 2012

In DuoProSS Meditech Corp. v. Inviro Medical Devices, Ltd., No 2012-1050, 2012 WL 3292920 (Fed. Cir. Aug. 14, 2012), the U.S. Court of Appeals for the Federal Circuit ruled that the Trademark Trial and Appeal Board erred in failing to cancel two trademark registrations for medical syringes designed to be broken so they could not be reused


Preventive care court decision
  • Kilpatrick Townsend & Stockton LLP
  • USA
  • November 19 2012

A federal judge in the District of Columbia circuit issued a stay from the contraceptive coverage mandate


Supreme Court decision to drop on Thursday
  • Kilpatrick Townsend & Stockton LLP
  • USA
  • June 25 2012

This morning the Supreme Court issued its ruling on the constitutionally of Arizona’s new immigration law


Federal Circuit's en banc decision delineates and defines a written description requirement
  • Kilpatrick Townsend & Stockton LLP
  • USA
  • March 24 2010

On March 22, the Federal Circuit issued its 9-2 en banc decision in Ariad Pharmaceuticals, Inc. v. Eli Lilly and Co., affirming 112, 1 contains a written description requirement that is separate and distinct from the enablement requirement